Related Experiment Video
Updated: Mar 21, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
Wirginia Likus1, Krzysztof Siemianowicz2, Konrad Bieńk3
1Department of Human Anatomy, School of Medicine in Katowice, Medical University of Silesia, 18 Medyków Street, 40-752 Katowice, Poland.
Abstract:
Understanding the connection between metabolic pathways and cancer is very important for the development of new therapeutic approaches based on regulatory enzymes in pathways associated with tumorigenesis. The mevalonate cascade and its rate-liming enzyme HMG CoA-reductase has recently drawn the attention of cancer researchers because strong evidences arising mostly from epidemiologic studies, show that it could promote transformation. Hence, these studies pinpoint HMG CoA-reductase as a candidate proto-oncogene. Several recent epidemiological studies, in different populations, have proven that statins are beneficial for the treatment-outcome of various cancers, and may improve common cancer therapy strategies involving alkylating agents, and antimetabolites. Cancer stem cells/cancer initiating cells (CSC) are key to cancer progression and metastasis. Therefore, in the current review we address the different effects of statins on cancer stem cells. The mevalonate cascade is among the most pleiotropic, and highly interconnected signaling pathways. Through G-protein-coupled receptors (GRCP), it integrates extra-, and intracellular signals. The mevalonate pathway is implicated in cell stemness, cell proliferation, and organ size regulation through the Hippo pathway (e.g. Yap/Taz signaling axis). This pathway is a prime preventive target through the administration of statins for the prophylaxis of obesity-related cardiovascular diseases. Its prominent role in regulation of cell growth and stemness also invokes its role in cancer development and progression. The mevalonate pathway affects cancer metastasis in several ways by: (i) affecting epithelial-to-mesenchymal transition (EMT), (ii) affecting remodeling of the cytoskeleton as well as cell motility, (iii) affecting cell polarity (non-canonical Wnt/planar pathway), and (iv) modulation of mesenchymal-to-epithelial transition (MET). Herein we provide an overview of the mevalonate signaling network. We then briefly highlight diverse functions of various elements of this mevalonate pathway. We further discuss in detail the role of elements of the mevalonate cascade in stemness, carcinogenesis, cancer progression, metastasis and maintenance of cancer stem cells.
Insights
Statins, drugs targeting the mevalonate pathway, show promise in cancer treatment by affecting cancer stem cells and metastasis. This pathway is crucial for cell growth, stemness, and cancer progression.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- The mevalonate pathway, regulated by HMG CoA-reductase, is implicated in cancer development and progression.
- Epidemiological studies suggest statins benefit cancer treatment outcomes and enhance conventional therapies.
- Cancer stem cells (CSCs) are critical drivers of tumor progression and metastasis.
Purpose of the Study:
- To review the multifaceted effects of statins on cancer stem cells.
- To elucidate the role of the mevalonate pathway in stemness, carcinogenesis, and metastasis.
- To highlight the mevalonate pathway's integration with signaling networks like Hippo and Wnt.
Main Methods:
- Literature review of epidemiological studies and molecular mechanisms.
- Analysis of the mevalonate pathway's role in cell signaling and cancer biology.
- Focus on statins' impact on cancer stem cells and metastatic processes.
Main Results:
- The mevalonate pathway regulates stemness, proliferation, and organ size via pathways like Hippo (Yap/Taz).
- Statins demonstrate potential in improving cancer treatment outcomes and inhibiting CSCs.
- The pathway influences metastasis through EMT, cytoskeleton remodeling, cell motility, and cell polarity.
Conclusions:
- The mevalonate pathway is a key regulator of cancer stemness, progression, and metastasis.
- Statins represent a promising therapeutic strategy targeting the mevalonate cascade in cancer.
- Targeting the mevalonate pathway offers potential for novel cancer prevention and treatment approaches.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance

